Company Overview
About Iambic Therapeutics
Iambic Therapeutics is a clinical-stage biotech founded in 2019, headquartered in San Diego, led by CEO Tom Miller. Integrates AI with physics-based modeling for small-molecule drug discovery. Proprietary platform includes Enchant (multimodal transformer) and NeuralPLexer (protein-ligand structure predictor).
Business Model & Competitive Advantage
Lead program IAM1363 is a brain-penetrant HER2 inhibitor in Phase 1/1b. Raised $100M+ in oversubscribed November 2025 round from Abingworth, Alexandria, ARK, Illumina Ventures. Named to CNBC 2025 Disruptor 50.
Competitive Landscape 2025–2026
February 2026: landmark Takeda collaboration for oncology, inflammation, and GI diseases with milestone payments exceeding $1.7B. Also partnered with Lundbeck for migraine and CNS. One of the most commercially validated AI drug discovery platforms.
Open Positions
Reddit Discussions
Key Differentiators
Strong Challenger
Iambic Therapeutics is an established challenger with significant market presence and competitive offerings in Healthcare Tech.
Enterprise Scale
With $1700M in revenue, Iambic Therapeutics operates at enterprise scale with proven market validation.
Frequently Asked Questions
Compare Iambic Therapeutics with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Start Comparison →Claim This Profile
Are you from Iambic Therapeutics? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Iambic Therapeutics Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Iambic Therapeutics vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →